News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Sandoz invests in new drug substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity
Sandoz announces USD 300 million investment in new drug substance facility in Ljubljana, Slovenia, to enhance biosimilar manufacturing capacity and support Bio100 goal -
-
COMMUNIQUÉ DE PRESSE
Sandoz hosts Capital Markets Day and unveils Bio100 ambition – maximising Sandoz value in its golden decade for biosimilars
Sandoz hosts Capital Markets Day unveiling Bio100 ambition to maximize value in golden decade for biosimilars. Strong growth plan aims for 100+ biosimilars by 2040 -
-
-
COMMUNIQUÉ DE PRESSE
Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline
Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, expanding industry-leading pipeline. Agreement includes cetuximab, evolocumab, belimumab biosimilars, and option for human hyaluronidase -
